142 related articles for article (PubMed ID: 23441851)
1. Substrate-specific conformational regulation of the receptor tyrosine kinase VEGFR2 catalytic domain.
Solowiej J; Chen JH; Zou HY; Grant SK; Murray BW
ACS Chem Biol; 2013 May; 8(5):978-86. PubMed ID: 23441851
[TBL] [Abstract][Full Text] [Related]
2. Characterizing the effects of the juxtamembrane domain on vascular endothelial growth factor receptor-2 enzymatic activity, autophosphorylation, and inhibition by axitinib.
Solowiej J; Bergqvist S; McTigue MA; Marrone T; Quenzer T; Cobbs M; Ryan K; Kania RS; Diehl W; Murray BW
Biochemistry; 2009 Jul; 48(29):7019-31. PubMed ID: 19526984
[TBL] [Abstract][Full Text] [Related]
3. Characterization and development of a peptide substrate-based phosphate transfer assay for the human vascular endothelial growth factor receptor-2 tyrosine kinase.
Zhao G; Peery RB; Yingling JM
Anal Biochem; 2007 Jan; 360(2):196-206. PubMed ID: 17141171
[TBL] [Abstract][Full Text] [Related]
4. Development and strategies of VEGFR-2/KDR inhibitors.
Huang L; Huang Z; Bai Z; Xie R; Sun L; Lin K
Future Med Chem; 2012 Sep; 4(14):1839-52. PubMed ID: 23043480
[TBL] [Abstract][Full Text] [Related]
5. YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.
Amino N; Ideyama Y; Yamano M; Kuromitsu S; Tajinda K; Samizu K; Hisamichi H; Matsuhisa A; Shirasuna K; Kudoh M; Shibasaki M
Clin Cancer Res; 2006 Mar; 12(5):1630-8. PubMed ID: 16533791
[TBL] [Abstract][Full Text] [Related]
6. Biochemical characterization of a novel type-II VEGFR2 kinase inhibitor: comparison of binding to non-phosphorylated and phosphorylated VEGFR2.
Iwata H; Imamura S; Hori A; Hixon MS; Kimura H; Miki H
Bioorg Med Chem; 2011 Sep; 19(18):5342-51. PubMed ID: 21885287
[TBL] [Abstract][Full Text] [Related]
7. Characterization and kinetic mechanism of catalytic domain of human vascular endothelial growth factor receptor-2 tyrosine kinase (VEGFR2 TK), a key enzyme in angiogenesis.
Parast CV; Mroczkowski B; Pinko C; Misialek S; Khambatta G; Appelt K
Biochemistry; 1998 Nov; 37(47):16788-801. PubMed ID: 9843450
[TBL] [Abstract][Full Text] [Related]
8. Acquired drug resistance to vascular endothelial growth factor receptor 2 tyrosine kinase inhibitor in human vascular endothelial cells.
Arao T; Matsumoto K; Furuta K; Kudo K; Kaneda H; Nagai T; Sakai K; Fujita Y; Tamura D; Aomatsu K; Koizumi F; Nishio K
Anticancer Res; 2011 Sep; 31(9):2787-96. PubMed ID: 21868521
[TBL] [Abstract][Full Text] [Related]
9. 2-((1H-Azol-1-yl)methyl)-N-arylbenzamides: novel dual inhibitors of VEGFR-1/2 kinases.
Kiselyov AS; Semenova M; Semenov VV; Piatnitski E
Bioorg Med Chem Lett; 2006 Mar; 16(6):1726-30. PubMed ID: 16364640
[TBL] [Abstract][Full Text] [Related]
10. Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors.
Timofeevski SL; McTigue MA; Ryan K; Cui J; Zou HY; Zhu JX; Chau F; Alton G; Karlicek S; Christensen JG; Murray BW
Biochemistry; 2009 Jun; 48(23):5339-49. PubMed ID: 19459657
[TBL] [Abstract][Full Text] [Related]
11. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
12. Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain.
Lee CC; Jia Y; Li N; Sun X; Ng K; Ambing E; Gao MY; Hua S; Chen C; Kim S; Michellys PY; Lesley SA; Harris JL; Spraggon G
Biochem J; 2010 Sep; 430(3):425-37. PubMed ID: 20632993
[TBL] [Abstract][Full Text] [Related]
13. A highly selective, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor has potent activity in vitro and in vivo.
LaMontagne KR; Butler J; Borowski VB; Fuentes-Pesquera AR; Blevitt JM; Huang S; Li R; Connolly PJ; Greenberger LM
Angiogenesis; 2009; 12(3):287-96. PubMed ID: 19544081
[TBL] [Abstract][Full Text] [Related]
14. Identification of potent and selective VEGFR receptor tyrosine kinase inhibitors having new amide isostere headgroups.
Gaudette F; Raeppel S; Nguyen H; Beaulieu N; Beaulieu C; Dupont I; Macleod AR; Besterman JM; Vaisburg A
Bioorg Med Chem Lett; 2010 Feb; 20(3):848-52. PubMed ID: 20071170
[TBL] [Abstract][Full Text] [Related]
15. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
Dalgarno D; Stehle T; Narula S; Schelling P; van Schravendijk MR; Adams S; Andrade L; Keats J; Ram M; Jin L; Grossman T; MacNeil I; Metcalf C; Shakespeare W; Wang Y; Keenan T; Sundaramoorthi R; Bohacek R; Weigele M; Sawyer T
Chem Biol Drug Des; 2006 Jan; 67(1):46-57. PubMed ID: 16492148
[TBL] [Abstract][Full Text] [Related]
16. Discovery of indenopyrazoles as EGFR and VEGFR-2 tyrosine kinase inhibitors by in silico high-throughput screening.
Usui T; Ban HS; Kawada J; Hirokawa T; Nakamura H
Bioorg Med Chem Lett; 2008 Jan; 18(1):285-8. PubMed ID: 17983745
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of benzamides and benzamidines as selective inhibitors of VEGFR tyrosine kinases.
Nakamura H; Sasaki Y; Uno M; Yoshikawa T; Asano T; Ban HS; Fukazawa H; Shibuya M; Uehara Y
Bioorg Med Chem Lett; 2006 Oct; 16(19):5127-31. PubMed ID: 16893647
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy.
Beebe JS; Jani JP; Knauth E; Goodwin P; Higdon C; Rossi AM; Emerson E; Finkelstein M; Floyd E; Harriman S; Atherton J; Hillerman S; Soderstrom C; Kou K; Gant T; Noe MC; Foster B; Rastinejad F; Marx MA; Schaeffer T; Whalen PM; Roberts WG
Cancer Res; 2003 Nov; 63(21):7301-9. PubMed ID: 14612527
[TBL] [Abstract][Full Text] [Related]
19. 2-(Quinazolin-4-ylamino)-[1,4]benzoquinones as covalent-binding, irreversible inhibitors of the kinase domain of vascular endothelial growth factor receptor-2.
Wissner A; Floyd MB; Johnson BD; Fraser H; Ingalls C; Nittoli T; Dushin RG; Discafani C; Nilakantan R; Marini J; Ravi M; Cheung K; Tan X; Musto S; Annable T; Siegel MM; Loganzo F
J Med Chem; 2005 Dec; 48(24):7560-81. PubMed ID: 16302797
[TBL] [Abstract][Full Text] [Related]
20. Structure activity relationships of chrysoeriol and analogs as dual c‑Met and VEGFR2 tyrosine kinase inhibitors.
Lai S; Chen JN; Huang HW; Zhang XY; Jiang HL; Li W; Wang PL; Wang J; Liu FN
Oncol Rep; 2018 Sep; 40(3):1650-1656. PubMed ID: 30015973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
